724 related articles for article (PubMed ID: 28731207)
1. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
3. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
Webster A; Pankhurst T; Rinaldi F; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004756. PubMed ID: 16625610
[TBL] [Abstract][Full Text] [Related]
4. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
5. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data.
Webster AC; Pankhurst T; Rinaldi F; Chapman JR; Craig JC
Transplantation; 2006 Apr; 81(7):953-65. PubMed ID: 16612264
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
8. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
9. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
[TBL] [Abstract][Full Text] [Related]
10. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
11. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins NG; Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002290. PubMed ID: 32297308
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
14. Steroid avoidance or withdrawal for kidney transplant recipients.
Haller MC; Royuela A; Nagler EV; Pascual J; Webster AC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD005632. PubMed ID: 27546100
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
16. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Vernooij RW; Michael M; Ladhani M; Webster AC; Strippoli GF; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2024 May; 5(5):CD003774. PubMed ID: 38700045
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
18. Interventions for minimal change disease in adults with nephrotic syndrome.
Azukaitis K; Palmer SC; Strippoli GF; Hodson EM
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD001537. PubMed ID: 35230699
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
20. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]